Low-Dose Brimonidine Preferential Vasoconstriction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing α-2 adrenergic receptor agonists, such as brimonidine, are associated with a high incidence of rebound hyperemia and other side effects, limiting their clinical use to short durations due to their inability to provide safe and long-term vasoconstriction.
Innovation Solution
The use of low doses of highly selective α-2 adrenergic receptor agonists, specifically brimonidine at concentrations below 0.05% weight by volume, to achieve preferential vasoconstriction of smaller blood vessels with reduced hyperemia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Force
If conventional alpha adrenergic receptor agonists (e.g., brimonidine at 0.1%-0.2%) are used to achieve vasoconstriction, then vasoconstrictive effect is improved, but rebound hyperemia occurs with high incidence
Solution Approach 1:
The patent applies parameter changes by reducing the concentration of brimonidine from conventional levels (0.1%-0.2%) to low levels (0.001%-0.05%), and by modifying the selectivity ratio (alpha-2 to alpha-1 binding affinity) to achieve preferential vasoconstriction of smaller blood vessels while minimizing rebound hyperemia. This parameter optimization resolves the contradiction between achieving sufficient vasoconstriction and avoiding harmful rebound effects.
2Force
If general alpha agonists with high alpha 1 receptor agonist activity are used for topical mucosal decongestant use, then vasoconstriction is achieved, but rebound hyperemia and medicamentosa occur restricting use to several hours or days
Solution Approach 1:
The patent changes the key parameter of receptor selectivity by using highly selective alpha-2 agonists with minimal alpha-1 activity, rather than general alpha agonists. This parameter change enables prolonged duration of safe use (weeks to months) by avoiding the rebound hyperemia and medicamentosa that limit general alpha agonists to only several hours or days of use.
3Power
If selective alpha-2 agonists are used at conventional concentrations to treat glaucoma, then intraocular pressure is lowered, but significant rebound hyperemia occurs
Solution Approach 1:
The patent applies parameter changes by reducing brimonidine concentration from conventional glaucoma treatment levels (0.1%-0.2%) to low levels (0.001%-0.05%). This parameter reduction maintains sufficient alpha-2 mediated intraocular pressure control while minimizing the harmful rebound hyperemia that occurs at higher concentrations, thereby resolving the contradiction between therapeutic efficacy and side effect prevention.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for safe and long-term vasoconstriction with significantly reduced rebound hyperemia, enabling prolonged therapeutic benefits without the adverse effects associated with higher doses.
Implementation Method 1
Adrenergic receptors mediate physiological responses to the catecholamines, norepinephrine and epinephrine... Vascular constriction is known to be mediated by α-adrenergic receptors. The α-2A, α-2B, and α-2C subtypes appear to regulate arterial and/or venular contraction in some vascular beds
Data Source
AI summary
The invention generally relates to compositions and methods for preferential vasoconstriction of smaller blood vessels relative to larger blood vessels. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.